COVID-19-Related Delays in Development and Supply Operations
First written in FY2020. 1 of 4 entries say "Softened", first in FY2021. Latest entry: FY2023.
SanBio moved to the "Worse" side of this theme in 2021.
2 other companies' latest entry also says "Restated".
- FY2023RestatedAnnual report
「The ongoing outbreak of COVID-19 has constrained various business activities of the Company Group, and as a result may delay the development of the Company Group’s regenerative cell therapy product SB623 and the subsequent establishment of its manufacturing, logistics and sales infrastructure.」
The possibility of delays to SB623’s development, manufacturing, logistics and sales infrastructure due to COVID-19 continues to be disclosed as a risk. - FY2022WorsenedAnnual report
「The ongoing outbreak of COVID-19 has constrained various business activities of the Company Group, and as a result may delay the development of the Company Group’s regenerative cell therapy product SB623 and the subsequent establishment of its manufacturing, logistics and sales infrastructure.」
The disclosure has returned from the previous statement that the impact on the operating environment was limited to explicitly stating the possibility of delays to SB623’s development, manufacturing, logistics and sales infrastructure. - FY2021SoftenedAnnual report
「At present, the impact of the ongoing COVID-19 outbreak on the operating environment is limited, but the Company will continue to monitor its impact on the Company Group’s various business activities.」
The possibility of delays to business activities, development and the supply infrastructure due to COVID-19 continues to be disclosed, while the Company indicated that the impact on the operating environment is limited at present. - FY2020First statedAnnual report
「The ongoing outbreak of COVID-19 has constrained various business activities of the Company Group. As a result, delays may occur in the development of the Company Group’s regenerative cell therapy product SB623 and in establishing the subsequent manufacturing, logistics and sales infrastructure. If the outbreak is prolonged, it may have a material impact on the Company Group’s financial position and operating results.」
The Company disclosed the possibility of delays to SB623’s development and to the establishment of its manufacturing, logistics and sales infrastructure as a new risk due to the COVID-19 pandemic.